Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women

Alexander Kucherov, Alex J. Polotsky, Marie Menke, Barbara Isaac, Beth McAvey, Erkan Buyuk, Andrew P. Bradford, Cheryl Hickmon, Beatrice Babbs, Sarah Berga, Tammy Loucks, Nanette Santoro

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To better understand the site and mode of action of aromatase inhibitors. Design: Prospective study. Setting: Academic research environment. Patient(s): Five eumenorrheic (without polycystic ovary syndrome), early follicular phase women with a normal body mass index (mean: 20.47 ± 0.68 kg/m 2), and 12 normal weight, midreproductive aged, early follicular phase women with a normal body mass index (mean: 20.8 ± 1.7 kg/m 2) as historical controls. Intervention(s): 2.5 mg letrozole daily for 7 days, with daily urine collection (first morning void), thrice weekly blood sampling, and 4 hours of blood sampling every 10 minutes. Main Outcome Measure(s): Serum luteinizing hormone (LH) measured by a well-characterized immunofluorometric assay with LH pulse characteristics compared between treated and control groups using t tests. Result(s): Mean LH and LH pulse amplitude more than doubled in the women who had taken letrozole compared with the controls, but the LH pulse frequency did not differ between the women taking letrozole and the controls. Conclusion(s): These results indicate that the release of negative feedback inhibition of estradiol on the hypothalamic-pituitary axis in normal women by aromatase inhibitors creates an amplitude-related increase in endogenous hypothalamic-pituitary drive. The finding that the mean LH and LH pulse amplitude, but not the frequency, increased after letrozole suggests a possible pituitary site of action.

Original languageEnglish (US)
Pages (from-to)2063-2066
Number of pages4
JournalFertility and Sterility
Volume95
Issue number6
DOIs
StatePublished - May 2011

Fingerprint

letrozole
Aromatase
Luteinizing Hormone
Aromatase Inhibitors
Follicular Phase
Body Mass Index
Fluoroimmunoassay
Urine Specimen Collection
Polycystic Ovary Syndrome
Estradiol
Outcome Assessment (Health Care)
Prospective Studies
Weights and Measures
Control Groups
Serum
Research

Keywords

  • Aromatase inhibitor
  • hypothalamic-pituitary-gonadal axis
  • letrozole
  • luteinizing hormone
  • ovary
  • pituitary

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women. / Kucherov, Alexander; Polotsky, Alex J.; Menke, Marie; Isaac, Barbara; McAvey, Beth; Buyuk, Erkan; Bradford, Andrew P.; Hickmon, Cheryl; Babbs, Beatrice; Berga, Sarah; Loucks, Tammy; Santoro, Nanette.

In: Fertility and Sterility, Vol. 95, No. 6, 05.2011, p. 2063-2066.

Research output: Contribution to journalArticle

Kucherov, A, Polotsky, AJ, Menke, M, Isaac, B, McAvey, B, Buyuk, E, Bradford, AP, Hickmon, C, Babbs, B, Berga, S, Loucks, T & Santoro, N 2011, 'Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women', Fertility and Sterility, vol. 95, no. 6, pp. 2063-2066. https://doi.org/10.1016/j.fertnstert.2011.01.158
Kucherov, Alexander ; Polotsky, Alex J. ; Menke, Marie ; Isaac, Barbara ; McAvey, Beth ; Buyuk, Erkan ; Bradford, Andrew P. ; Hickmon, Cheryl ; Babbs, Beatrice ; Berga, Sarah ; Loucks, Tammy ; Santoro, Nanette. / Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women. In: Fertility and Sterility. 2011 ; Vol. 95, No. 6. pp. 2063-2066.
@article{de0772578e5849a29917ad30530fc7e0,
title = "Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women",
abstract = "Objective: To better understand the site and mode of action of aromatase inhibitors. Design: Prospective study. Setting: Academic research environment. Patient(s): Five eumenorrheic (without polycystic ovary syndrome), early follicular phase women with a normal body mass index (mean: 20.47 ± 0.68 kg/m 2), and 12 normal weight, midreproductive aged, early follicular phase women with a normal body mass index (mean: 20.8 ± 1.7 kg/m 2) as historical controls. Intervention(s): 2.5 mg letrozole daily for 7 days, with daily urine collection (first morning void), thrice weekly blood sampling, and 4 hours of blood sampling every 10 minutes. Main Outcome Measure(s): Serum luteinizing hormone (LH) measured by a well-characterized immunofluorometric assay with LH pulse characteristics compared between treated and control groups using t tests. Result(s): Mean LH and LH pulse amplitude more than doubled in the women who had taken letrozole compared with the controls, but the LH pulse frequency did not differ between the women taking letrozole and the controls. Conclusion(s): These results indicate that the release of negative feedback inhibition of estradiol on the hypothalamic-pituitary axis in normal women by aromatase inhibitors creates an amplitude-related increase in endogenous hypothalamic-pituitary drive. The finding that the mean LH and LH pulse amplitude, but not the frequency, increased after letrozole suggests a possible pituitary site of action.",
keywords = "Aromatase inhibitor, hypothalamic-pituitary-gonadal axis, letrozole, luteinizing hormone, ovary, pituitary",
author = "Alexander Kucherov and Polotsky, {Alex J.} and Marie Menke and Barbara Isaac and Beth McAvey and Erkan Buyuk and Bradford, {Andrew P.} and Cheryl Hickmon and Beatrice Babbs and Sarah Berga and Tammy Loucks and Nanette Santoro",
year = "2011",
month = "5",
doi = "10.1016/j.fertnstert.2011.01.158",
language = "English (US)",
volume = "95",
pages = "2063--2066",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women

AU - Kucherov, Alexander

AU - Polotsky, Alex J.

AU - Menke, Marie

AU - Isaac, Barbara

AU - McAvey, Beth

AU - Buyuk, Erkan

AU - Bradford, Andrew P.

AU - Hickmon, Cheryl

AU - Babbs, Beatrice

AU - Berga, Sarah

AU - Loucks, Tammy

AU - Santoro, Nanette

PY - 2011/5

Y1 - 2011/5

N2 - Objective: To better understand the site and mode of action of aromatase inhibitors. Design: Prospective study. Setting: Academic research environment. Patient(s): Five eumenorrheic (without polycystic ovary syndrome), early follicular phase women with a normal body mass index (mean: 20.47 ± 0.68 kg/m 2), and 12 normal weight, midreproductive aged, early follicular phase women with a normal body mass index (mean: 20.8 ± 1.7 kg/m 2) as historical controls. Intervention(s): 2.5 mg letrozole daily for 7 days, with daily urine collection (first morning void), thrice weekly blood sampling, and 4 hours of blood sampling every 10 minutes. Main Outcome Measure(s): Serum luteinizing hormone (LH) measured by a well-characterized immunofluorometric assay with LH pulse characteristics compared between treated and control groups using t tests. Result(s): Mean LH and LH pulse amplitude more than doubled in the women who had taken letrozole compared with the controls, but the LH pulse frequency did not differ between the women taking letrozole and the controls. Conclusion(s): These results indicate that the release of negative feedback inhibition of estradiol on the hypothalamic-pituitary axis in normal women by aromatase inhibitors creates an amplitude-related increase in endogenous hypothalamic-pituitary drive. The finding that the mean LH and LH pulse amplitude, but not the frequency, increased after letrozole suggests a possible pituitary site of action.

AB - Objective: To better understand the site and mode of action of aromatase inhibitors. Design: Prospective study. Setting: Academic research environment. Patient(s): Five eumenorrheic (without polycystic ovary syndrome), early follicular phase women with a normal body mass index (mean: 20.47 ± 0.68 kg/m 2), and 12 normal weight, midreproductive aged, early follicular phase women with a normal body mass index (mean: 20.8 ± 1.7 kg/m 2) as historical controls. Intervention(s): 2.5 mg letrozole daily for 7 days, with daily urine collection (first morning void), thrice weekly blood sampling, and 4 hours of blood sampling every 10 minutes. Main Outcome Measure(s): Serum luteinizing hormone (LH) measured by a well-characterized immunofluorometric assay with LH pulse characteristics compared between treated and control groups using t tests. Result(s): Mean LH and LH pulse amplitude more than doubled in the women who had taken letrozole compared with the controls, but the LH pulse frequency did not differ between the women taking letrozole and the controls. Conclusion(s): These results indicate that the release of negative feedback inhibition of estradiol on the hypothalamic-pituitary axis in normal women by aromatase inhibitors creates an amplitude-related increase in endogenous hypothalamic-pituitary drive. The finding that the mean LH and LH pulse amplitude, but not the frequency, increased after letrozole suggests a possible pituitary site of action.

KW - Aromatase inhibitor

KW - hypothalamic-pituitary-gonadal axis

KW - letrozole

KW - luteinizing hormone

KW - ovary

KW - pituitary

UR - http://www.scopus.com/inward/record.url?scp=79955016311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955016311&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2011.01.158

DO - 10.1016/j.fertnstert.2011.01.158

M3 - Article

C2 - 21353673

AN - SCOPUS:79955016311

VL - 95

SP - 2063

EP - 2066

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -